Name: UCB SA (UCB) Stock
Brand: UCB SA
Rating: 6 (3 reviews)

Question 1

What does UCB do?

Accepted Answer

UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees.  In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Question 2

Can you provide the latest stock price for UCB SA?

Accepted Answer

The current stock price of UCB.BR is 251.7 EUR. The price decreased by -1.72% in the last trading session.

Question 3

What is the dividend status of UCB SA?

Accepted Answer

UCB SA (UCB.BR) has a dividend yield of 0.41%. The yearly dividend amount is currently 1.36.

Question 4

What is the ChartMill rating of UCB SA stock?

Accepted Answer

UCB.BR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.

Question 5

Can you provide the PE ratio for UCB stock?

Accepted Answer

The PE ratio for UCB SA (UCB.BR) is 39.21. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 251.7 EUR.

Question 6

What is UCB SA worth?

Accepted Answer

UCB SA (UCB.BR) has a market capitalization of 48.96B EUR. This makes UCB.BR a Large Cap stock.

UCB SA (UCB.BR) Stock Price, Forecast & Analysis

UCB.BR Latest News, Press Relases and Analysis